Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Announces Target Price $4
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Cuts Target Price to $20
Checkpoint Therapeutics Analyst Ratings
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Checkpoint Therapeutics Analyst Ratings
HC Wainwright & Co. : Checkpoint Therapeutics (CKPT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $34.00.
Checkpoint Therapeutics Analyst Ratings
Buy Rating Affirmed for Checkpoint Therapeutics Despite FDA Setback: Solid Clinical Data Fuels Optimism for 2024 Market Entry
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating
Analyst Maintains Buy Rating for Checkpoint Therapeutics Amid FDA Setback, Citing Strong Approval Prospects and Market Potential
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Checkpoint Therapeutics Analyst Ratings
No Data